EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Development of a Medication-Use Evaluation Template for Andexanet Alfa in the Reversal of Anticoagulation With Factor Xa Inhibitors

Toni Fera, Allison Burnett, Jessica Grandoni, Mary R Moore, Barbara B Nussbaum, Charles V Pollack, Anne E Rose, Sarah A Spinler, Michael B Streiff, Charles J Turck iD, John Fanikos

Journal of Pharmacy Practice · 2025

DOI: 10.1177/08971900241263164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy Practice, 2025. Verfasst von Toni Fera und 10 weiteren Autor:innen. Beteiligte Einrichtung: Project Consultant, Greater Pittsburgh Area, PA, USA. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Recombinant Proteins, Factor Xa. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medication-use evaluations are meant to ensure that medication-use processes are consistent with prevailing standards of care, assure optimal use of therapy, and reduce the risk of medication-related problems. Reversal agents for direct oral anticoagulants are a worthy focus for medication-use evaluations for reasons of efficacy, safety, and cost. A multidisciplinary team of experts developed 2 medication-use evaluation templates illustrating the application of professional society guidelines to the appropriate use of andexanet alfa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor Xa InhibitorsRecombinant ProteinsFactor XaHumansAnticoagulantsBlood Coagulation

Stichwörter der Autor:innen

andexanet alfaanticoagulant reversal agentshemorrhageintracranial hemorrhagesmedication review

Substanzen

PRT064445Factor Xa InhibitorsRecombinant ProteinsFactor XaAnticoagulants

Autor:innen und Institutionen

  • Project Consultant, Greater Pittsburgh Area, PA, USA.
  • Inpatient Antithrombosis Stewardship Service, University of New Mexico Hospital, Albuquerque, NM, USA.
  • Department of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.
  • Mass General Brigham, Boston, MA, USA.
  • ASHP Research and Education Foundation, Bethesda, MD, USA.
  • Department of Emergency Medicine, University of Mississippi, Jackson, MS, USA.

ORCID-Profile: Charles J Turck

Förderung

  • Alexion, AstraZeneca Rare Disease

Zitieren

APA

Fera, T., Burnett, A., Grandoni, J., Moore, M. R., Nussbaum, B. B., Pollack, C. V., Rose, A. E., Spinler, S. A., Streiff, M. B., Turck, C. J., & Fanikos, J. (2025). Development of a Medication-Use Evaluation Template for Andexanet Alfa in the Reversal of Anticoagulation With Factor Xa Inhibitors. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900241263164

Vancouver

Fera T, Burnett A, Grandoni J, Moore MR, Nussbaum BB, Pollack CV, et al. Development of a Medication-Use Evaluation Template for Andexanet Alfa in the Reversal of Anticoagulation With Factor Xa Inhibitors. Journal of Pharmacy Practice. 2025. doi:10.1177/08971900241263164

BibTeX
@article{Fera2025,
  author = {Fera, Toni and Burnett, Allison and Grandoni, Jessica and Moore, Mary R and Nussbaum, Barbara B and Pollack, Charles V and Rose, Anne E and Spinler, Sarah A and Streiff, Michael B and Turck, Charles J and Fanikos, John},
  title = {Development of a Medication-Use Evaluation Template for Andexanet Alfa in the Reversal of Anticoagulation With Factor Xa Inhibitors},
  journal = {Journal of Pharmacy Practice},
  year = {2025},
  doi = {10.1177/08971900241263164}
}
Kostenlos starten →